Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
GDR.L
STRONG SELLgenedrive plc · Healthcare · United Kingdom · $28M · Avg Vol: $53K/d
COMPANY DESCRIPTION
genedrive plc is a molecular diagnostics company that designs, manufactures, and commercializes rapid, point-of-care pharmacogenetic tests. The company's competitive moat is built around its proprietary Genedrive platform, which delivers actionable genetic results in clinical settings to prevent adverse drug reactions, such as antibiotic-induced hearing loss. It operates as a niche healthcare technology developer at the forefront of personalized medicine and decentralized diagnostic testing.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 64.7K | 72.6K | 0.4M | 1.0M | 149.8% | 1.5M |
| EPS | -0.00 | -0.00 | -0.02 | -0.00 | — | -0.01 |
| Shares | 1.6B | 1.6B | 1.6B | 1.6B | 0.0% | 1.6B |
| Debt | 21.1K | 0.3M | 25.1K | 0 | 9.0% | 0.7M |
| Equity | 7.4M | 2.7M | 7.1M | 1.9M | -36.5% | — |
| Op CF | -6.1M | -5.0M | -5.0M | -6.8M | — | -5.1M |
| Inv CF | 38.3K | -10.6K | 1.3K | 26.4K | — | — |
| Fin CF | 8.7M | 2.4M | 8.4M | 1.5M | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GDR.L are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GDR.L | genedrive plc(you) | $28M | 16 | STRONG SELL |
| CLBX.L | CelLBxHealth plc | $39M | 16 | STRONG SELL |
| EDX.L | EDX Medical Group Plc | $65M | 6 | STRONG SELL |
| ABDX.L | Abingdon Health Plc | $34M | 41 | HOLD |
| HVO.L | hVIVO plc | $63M | 36 | HOLD |
| IXI.L | IXICO plc | $25M | 24 | SELL |
| SAR.L | Sareum Holdings plc | $38M | 19 | STRONG SELL |
| SBTX.L | SkinBioTherapeutics plc | $42M | 19 | STRONG SELL |
| APTA.L | Aptamer Group PLC | $25M | 4 | STRONG SELL |
| IMM.L | ImmuPharma plc | $31M | 2 | STRONG SELL |
Peer medians: ROE 0.2% · P/E 24.7x · Gross margin 56.3%